Browse MCM10

Summary
SymbolMCM10
Nameminichromosome maintenance 10 replication initiation factor
Aliases PRO2249; CNA43; DNA43; MCM10 minichromosome maintenance deficient 10 (S. cerevisiae); minichromosome mainten ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Note=Colocalizes with ORC2 in nuclei foci. Associated with chromatin in S phase. From early to mid-S phase located in discrete nuclear foci. In early S phase, several hundred foci appeared throughout the nucleus. In mid-S phase, the foci appeared at the nuclear periphery and nucleolar regions. In the late S and G phases localized to nucleoli.
Domain PF09332 Mcm10 replication factor
PF09329 Primase zinc finger
Function

Acts as a replication initiation factor that brings together the MCM2-7 helicase and the DNA polymerase alpha/primase complex in order to initiate DNA replication. Additionally, plays a role in preventing DNA damage during replication. Key effector of the RBBP6 and ZBTB38-mediated regulation of DNA-replication and common fragile sites stability; acts as a direct target of transcriptional repression by ZBTB38 (PubMed:24726359).

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0006260 DNA replication
GO:0006261 DNA-dependent DNA replication
GO:0006270 DNA replication initiation
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
Molecular Function GO:0003688 DNA replication origin binding
GO:0003697 single-stranded DNA binding
Cellular Component GO:0005657 replication fork
GO:0031298 replication fork protection complex
GO:0043596 nuclear replication fork
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-176187: Activation of ATR in response to replication stress
R-HSA-68962: Activation of the pre-replicative complex
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-69306: DNA Replication
R-HSA-69002: DNA Replication Pre-Initiation
R-HSA-69206: G1/S Transition
R-HSA-69481: G2/M Checkpoints
R-HSA-68874: M/G1 Transition
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-69304: Regulation of DNA replication
R-HSA-69300: Removal of licensing factors from origins
Summary
SymbolMCM10
Nameminichromosome maintenance 10 replication initiation factor
Aliases PRO2249; CNA43; DNA43; MCM10 minichromosome maintenance deficient 10 (S. cerevisiae); minichromosome mainten ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MCM10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMCM10
Nameminichromosome maintenance 10 replication initiation factor
Aliases PRO2249; CNA43; DNA43; MCM10 minichromosome maintenance deficient 10 (S. cerevisiae); minichromosome mainten ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MCM10 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.52 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMCM10
Nameminichromosome maintenance 10 replication initiation factor
Aliases PRO2249; CNA43; DNA43; MCM10 minichromosome maintenance deficient 10 (S. cerevisiae); minichromosome mainten ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MCM10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3330.224
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0610.929
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5420.406
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2040.693
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2770.85
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8210.684
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0130.973
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3730.721
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5670.573
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0890.845
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3610.536
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.577.48e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MCM10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMCM10
Nameminichromosome maintenance 10 replication initiation factor
Aliases PRO2249; CNA43; DNA43; MCM10 minichromosome maintenance deficient 10 (S. cerevisiae); minichromosome mainten ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MCM10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMCM10
Nameminichromosome maintenance 10 replication initiation factor
Aliases PRO2249; CNA43; DNA43; MCM10 minichromosome maintenance deficient 10 (S. cerevisiae); minichromosome mainten ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MCM10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MCM10.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMCM10
Nameminichromosome maintenance 10 replication initiation factor
Aliases PRO2249; CNA43; DNA43; MCM10 minichromosome maintenance deficient 10 (S. cerevisiae); minichromosome mainten ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MCM10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMCM10
Nameminichromosome maintenance 10 replication initiation factor
Aliases PRO2249; CNA43; DNA43; MCM10 minichromosome maintenance deficient 10 (S. cerevisiae); minichromosome mainten ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MCM10 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMCM10
Nameminichromosome maintenance 10 replication initiation factor
Aliases PRO2249; CNA43; DNA43; MCM10 minichromosome maintenance deficient 10 (S. cerevisiae); minichromosome mainten ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MCM10 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMCM10
Nameminichromosome maintenance 10 replication initiation factor
Aliases PRO2249; CNA43; DNA43; MCM10 minichromosome maintenance deficient 10 (S. cerevisiae); minichromosome mainten ......
Chromosomal Location10p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MCM10 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.